Please check your internet connection and try again.
# Ciproxin (Ciprofloxacin)
## Overview
Ciprofloxacin is a broad-spectrum second-generation fluoroquinolone antibiotic. It functions by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. It is highly effective against Gram-negative organisms (including *Pseudomonas aeruginosa*) but has limited activity against Gram-positive bacteria and anaerobes.
## Primary Indications
* Urinary tract infections (UTIs)
* Respiratory tract infections (excluding *S. pneumoniae* pneumonia)
* Bacterial gastroenteritis
* Bone and joint infections
* Abdominal infections (in combination with metronidazole)
* Inhalation anthrax (post-exposure prophylaxis and treatment)
## Adult Dosing
* **Uncomplicated UTI:** 250 mg orally every 12 hours for 3 days.
* **Complicated UTI / Pyelonephritis:** 500 mg orally every 12 hours for 7–14 days.
* **Respiratory/Abdominal infections:** 500–750 mg orally, or 400 mg IV, every 12 hours.
* **Maximum Dose:** Generally 1.5 g/day for routine infections; up to 1.5 g/day is standard for severe infections.
## Pediatric Dosing
*Usage is limited due to potential for arthropathy; reserved for indications where benefits outweigh risks or no safe alternative exists.*
* **Complicated UTI / Pyelonephritis:** 10–20 mg/kg every 12 hours (max 750 mg/dose).
* **Inhalation Anthrax:** 15 mg/kg every 12 hours (max 500 mg/dose).
* *Note: Always consult local pediatric infectious disease protocols for dosing adjustments based on body weight.*
## Dose Adjustments
* **Renal Impairment:** Requires dose reduction if CrCl ≤ 50 mL/min. Example: 250–500 mg every 24 hours depending on severity.
* **Hepatic Impairment:** No specific adjustment required, but use with caution.
## Contraindications
* Hypersensitivity to fluoroquinolones.
* Concomitant administration with tizanidine.
* History of myasthenia gravis (can exacerbate muscle weakness).
## Adverse Effects
* **Common:** Nausea, diarrhea, vomiting, rash.
* **Serious (Black Box Warnings):** Tendonitis and tendon rupture (risk increased in patients >60 years or on corticosteroids), peripheral neuropathy, CNS effects (seizures, psychosis), and QT interval prolongation.
* **Other:** *C. difficile*-associated diarrhea, hypoglycemia (especially in diabetic patients), and aortic aneurysm/dissection.
## Key Drug Interactions
* **Chelation:** Fluoroquinolones bind to antacids (magnesium, aluminum, calcium), iron, zinc, and sucralfate. Separate doses by at least 2 hours before or 6 hours after these products.
* **CYP450 Inhibitors/Substrates:** Ciprofloxacin is a moderate inhibitor of CYP1A2; increases levels of theophylline, caffeine, and tizanidine.
* **QT Prolonging Agents:** Risk of Torsades de Pointes increases with concurrent use (e.g., amiodarone, ondansetron).
## Monitoring
* **Renal Function:** Monitor creatinine clearance periodically during therapy.
* **Blood Glucose:** Monitor in patients with diabetes.
* **Cardiac:** ECG monitoring if high risk for QT prolongation.
* **Symptoms:** Monitor for sudden tendon pain or neurologic changes.
## Clinical Pearls
* **Photo-sensitivity:** Advise patients to avoid excessive sunlight or UV light.
* **Hydration:** Ensure adequate fluid intake to prevent crystalluria.
* **Food:** Ciprofloxacin absorption is not significantly affected by food, but milk/dairy products taken alone can interfere; take 2 hours before or 6 hours after dairy.
* **MRSA:** Highly unreliable for MRSA coverage; do not use empirically.
***
**Educational Disclaimer:** This information is for educational purposes and does not constitute medical advice. Clinical practice guidelines vary by institution and region. Always verify specific dosing, safety, and contraindications against institutional protocols and the most current version of the manufacturer’s product insert before prescribing or administering medication.
